Distribution Management Selects Onward Robotics for Automated Order Fulfillment, Leading 3PL Deploying 30+ Lumabots in Q1 2025
PITTSBURGH, March 5, 2025 /PRNewswire/ -- Onward Robotics, the pioneering mobile robotics and software company, today announced that it has entered into an agreement to provide its Meet Me® automation solution to Distribution Management, a leading distributor and national third-party logistics (3PL) provider with more than 50 years of expertise in distribution and fulfillment. Distribution Management (DM) will use Onward Robotics' revolutionary Pyxis software and 30+ Lumabot® autonomous mobile robots in its St. Peters, Missouri, fulfillment center with potential to expand to multiple DM sites in 2025.
Installing in Q1 of this year, Onward's person-to-goods automation solution will enhance DM's distribution flow and management of goods, supporting the 3PL's ability to process orders quickly and maintain its impressive record of delivering 99.98% order accuracy. Onward Robotics' unique Meet Me model decouples the work of fulfillment associates and Lumabot AMRs, allowing each to function as independent agents of the overall system. Proprietary Pyxis technology uses intelligent mission planning and dynamic labor balancing to optimize task management: reducing unproductive travel time, increasing flexibility, and delivering the capacity to move more orders, more efficiently.
'DM is committed to remaining on the forefront of innovation by implementing cutting-edge automation and robotic technologies that drive operational excellence for our customers,' said Rick Goe, SVP of Supply Chain Management at Distribution Management. 'Onward's Meet Me solution is an intelligent, scalable, and flexible way to increase efficiency and optimize order-picking workflows in our fulfillment centers.'
'DM has an established history of order fulfillment and inventory management innovation, and we're proud they've recognized Onward's Meet Me solution as the breakthrough industry leader in automated order fulfillment,' said Onward Robotics CEO Lance VandenBrook. 'Onward is committed to helping DM and its customers gain efficiency and flexibility in their supply chain operations, and we're looking forward to shared successes and future innovation with the DM team.'
About Distribution Management
Distribution Management (DM) is a U.S.-based 3rd Party Fulfillment (3PL) provider for consumer brands and a wholesale distributor serving the imaging reseller channel. With over 50 years in business, DM is an expert in automation, inventory management and order fulfillment addressing specific business needs within eCommerce logistics. The company strives to deliver fast, efficient and accurate order fulfillment that elevates the customer experience at every touchpoint.
About Onward Robotics
Onward Robotics delivers innovative automation technology that coordinates humans and robots as a cohesive system to revolutionize fulfillment. Our Meet Me® solution combines proprietary software with person-to-goods mobile robots to increase efficiency in warehousing, distribution, and e-commerce operations. Onward Robotics provides the boost in productivity, flexibility, and speed that companies need to remain competitive and grow. Learn more at onwardrobotics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.
Business Wire
3 hours ago
- Business Wire
Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer
SAN FRANCISCO--(BUSINESS WIRE)--Levi Strauss & Co. (LS&Co., NYSE: LEVI) today announced the appointment of Chris Callieri as senior vice president and chief supply chain officer, effective September 15. Reporting to Michelle Gass, president and chief executive officer, Callieri will join the company's executive leadership team and will be responsible for the global supply chain operations for the Levi's® brand. His responsibilities include product development, sourcing, global supply management, sustainability, and distribution and logistics. 'We're excited to welcome Chris to LS&Co. at this pivotal moment in our evolution into a DTC-first denim lifestyle company," said Gass. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation, and advance our sustainability goals — all while delivering exceptional value to our fans worldwide. " Callieri brings more than 20 years of international supply chain experience in the retail and consumer goods industries. He joins LS&Co. from Victoria's Secret & Co., where he served as chief supply chain officer, leading a global team across multiple geographies and overseeing product development, sourcing, production, and distribution and logistics for various categories including intimates, apparel, accessories and beauty. Previously he was at Tory Burch, where he was pivotal in implementing systems like PLM, Merchandise Planning and SAP, and led the transformation of the supply chain. Chris has a long-standing commitment to sustainability and established Tory Burch's sustainability team and strategy. Prior to Tory Burch, Callieri held senior roles at Adidas, including senior vice president, product operations, where he was responsible for materials development, product development, sourcing and logistics for Adidas Lifestyle Brands. Callieri's extensive experience also includes leadership roles at HRC Advisory and A.T. Kearney, where he led various transformation initiatives and developed strategies to improve supply chain responsiveness and product innovation for leading retailers. 'I'm thrilled to join LS&Co. at such an exciting time for the iconic Levi's® brand, a true category leader that thrives at the center of culture," Callieri said. "I look forward to working with the talented LS&Co. team to deliver strong performance, serve our fans around the world, and strengthen Levi's® position as the world's definitive denim lifestyle brand." About Levi Strauss & Co. Levi Strauss & Co. (LS&Co.) is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's®, Levi Strauss Signature™ and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,400 retail stores and shop-in-shops. Levi Strauss & Co.'s reported 2024 net revenues were $6.4 billion. For more information, go to and for financial news and announcements go to
Yahoo
4 hours ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
